Ryo Yamasaki Selected Research

Connexin 30

8/2018	Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model.
1/2018	Connexin 30 Deficiency Attenuates Chronic but Not Acute Phases of Experimental Autoimmune Encephalomyelitis Through Induction of Neuroprotective Microglia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ryo Yamasaki Research Topics

Disease

20	Multiple Sclerosis 01/2021 - 01/2013
12	Demyelinating Diseases (Demyelinating Disease) 06/2021 - 01/2013
12	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 11/2020 - 08/2013
10	Neuromyelitis Optica (Devic's Disease) 01/2021 - 01/2013
9	Polyneuropathies (Polyneuropathy) 11/2020 - 10/2015
8	Alzheimer Disease (Alzheimer's Disease) 04/2022 - 01/2011
7	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 12/2021 - 05/2010
7	Inflammation (Inflammations) 01/2021 - 07/2011
6	Guillain-Barre Syndrome 12/2020 - 07/2011
5	Neuralgia (Stump Neuralgia) 01/2021 - 11/2016
5	Disease Progression 01/2018 - 05/2010
4	Neuroinflammatory Diseases 06/2021 - 08/2017
4	Parkinson Disease (Parkinson's Disease) 01/2020 - 02/2011
4	Pain (Aches) 01/2020 - 01/2018
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2020 - 01/2018
3	Motor Neuron Disease (Primary Lateral Sclerosis) 12/2021 - 05/2010
3	Ataxia (Dyssynergia) 04/2021 - 11/2016
3	Atrophy 06/2019 - 04/2004
3	Hyperalgesia 01/2019 - 11/2016
2	Small Fiber Neuropathy 05/2022 - 01/2021
2	Myelitis 06/2021 - 11/2016
2	Vasculitis (Vasculitides) 05/2021 - 10/2015
2	Infections 05/2021 - 07/2010
2	Nervous System Diseases (Neurological Disorders) 01/2021 - 01/2018
2	Multiple System Atrophy 12/2020 - 01/2017
2	Hypertrophy 11/2020 - 10/2015
2	Muscle Weakness 10/2020 - 04/2019
2	Cerebral Hemorrhage 07/2020 - 06/2009
2	Ischemia 01/2020 - 01/2018
2	Insulin Resistance 01/2020 - 01/2017
2	Stroke (Strokes) 11/2019 - 01/2019
2	Ischemic Stroke 11/2019 - 01/2019
2	Meningitis 01/2019 - 01/2019
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 11/2017
2	Spastic Paraparesis 05/2016 - 02/2014
2	Leukocytosis (Pleocytosis) 07/2010 - 04/2010
1	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 05/2021
1	Facial Paralysis (Facial Palsy) 04/2021
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2021
1	Hypersensitivity (Allergy) 01/2021
1	Spinocerebellar Degenerations (Marinesco Sjogren Syndrome) 12/2020
1	Heart Failure 10/2020
1	Muscular Diseases (Myopathy) 10/2020
1	Scleromyxedema (Lichen Myxedematosus) 10/2020
1	Vacuolar myopathy 10/2020
1	Trigeminal Nerve Diseases (Trigeminal Nerve Disorders) 01/2020

Drug/Important Bio-Agent (IBA)

19	AntibodiesIBA 01/2021 - 07/2010
15	Immunoglobulin G (IgG)IBA 01/2021 - 07/2010
13	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2011
7	AutoantibodiesIBA 01/2021 - 12/2016
7	CytokinesIBA 11/2019 - 05/2010
6	Connexin 43 (Connexin43)IBA 06/2021 - 01/2013
5	Biomarkers (Surrogate Marker)IBA 12/2020 - 07/2014
5	Amyloid (Amyloid Fibrils)IBA 01/2020 - 02/2011
5	Myelin-Oligodendrocyte GlycoproteinIBA 01/2020 - 03/2014
5	ChemokinesIBA 11/2019 - 05/2010
4	plexinIBA 01/2021 - 01/2018
4	Intravenous Immunoglobulins (IVIG)FDA Link 10/2020 - 01/2011
4	HLA-DRB1 Chains (HLA DRB1)IBA 07/2020 - 11/2013
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2019 - 05/2010
4	AntigensIBA 01/2019 - 08/2013
3	ConnexinsIBA 06/2021 - 03/2014
3	Prednisolone (Predate)FDA LinkGeneric 10/2020 - 04/2010
3	Superoxide Dismutase-1IBA 01/2018 - 04/2012
3	Apomorphine FDA Link 01/2017 - 01/2011
2	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 05/2021 - 07/2014
2	GadoliniumIBA 04/2021 - 06/2009
2	AllergensIBA 01/2021 - 11/2019
2	Myelin-Associated GlycoproteinIBA 11/2020 - 12/2016
2	Fingolimod Hydrochloride (FTY720)FDA Link 07/2020 - 01/2014
2	Tissue Plasminogen Activator (Alteplase)FDA Link 07/2020 - 11/2019
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2020 - 01/2016
2	Peptides (Polypeptides)IBA 01/2020 - 01/2018
2	LectinsIBA 01/2020 - 01/2018
2	Interleukin-6 (Interleukin 6)IBA 11/2019 - 01/2017
2	Mitochondrial DNA (mtDNA)IBA 04/2019 - 02/2014
2	Glial Fibrillary Acidic ProteinIBA 01/2019 - 03/2014
2	BQ 788IBA 01/2019 - 11/2016
2	Immunoglobulins (Immunoglobulin)IBA 01/2019 - 01/2013
2	Connexin 30IBA 08/2018 - 01/2018
2	Glutamic Acid (Glutamate)FDA Link 01/2018 - 01/2017
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018 - 11/2016
2	HLA-DRB1*04 antigenIBA 01/2018 - 01/2016
2	Complement System Proteins (Complement)IBA 01/2018 - 01/2013
2	Methylprednisolone FDA LinkGeneric 01/2016 - 04/2010
2	DNA (Deoxyribonucleic Acid)IBA 02/2014 - 07/2010
2	Dopamine Agonists (Dopamine Agonist)IBA 02/2011 - 01/2011
1	8-hydroxyguanineIBA 04/2022
1	Mutant Proteins (Protein, Mutant)IBA 12/2021
1	CC ChemokinesIBA 12/2021
1	Immunosuppressive Agents (Immunosuppressants)IBA 05/2021
1	edoxabanIBA 01/2021
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 10/2020
1	MucinsIBA 10/2020
1	Antinuclear AntibodiesIBA 02/2020
1	connexin 47IBA 01/2020
1	Insulin (Novolin)FDA Link 01/2020

Therapy/Procedure

8	Therapeutics 05/2022 - 07/2010
5	Immunotherapy 10/2020 - 02/2014
2	Deep Brain Stimulation 01/2020 - 06/2009